| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | TRA2A |
| Uniprot No | Q13595 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 2-282 aa |
| 活性数据 | SDVEENNFE GRESRSQSKS PTGTPARVKS ESRSGSRSPS RVSKHSESHS RSRSKSRSRS RRHSHRRYTR SRSHSHSHRR RSRSRSYTPE YRRRRSRSHS PMSNRRRHTG SRANPDPNTC LGVFGLSLYT TERDLREVFS RYGPLSGVNV VYDQRTGRSR GFAFVYFERI DDSKEAMERA NGMELDGRRI RVDYSITKRA HTPTPGIYMG RPTHSGGGGG GGGGGGGGGG GRRRDSYYDR GYDRGYDRYE DYDYRYRRRS PSPYYSRYRS RSRSRSYSPR RY |
| 分子量 | 32.6 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人TRA2A蛋白的3篇代表性文献示例(内容基于研究领域共性，非真实文献，仅作参考)：
1. **文献名称**：*TRA2A promotes hepatocellular carcinoma progression by regulating CDK2 via alternative splicing*
**作者**：Li et al., 2020
**摘要**：研究揭示了TRA2A通过调控细胞周期相关基因(如CDK2)的选择性剪接，促进肝癌细胞增殖和迁移的分子机制，并证明其高表达与患者预后不良相关。
2. **文献名称**：*Structural insights into the RNA-binding specificity of human TRA2A protein*
**作者**：Zhang et al., 2018
**摘要**：通过X射线晶体学解析了TRA2A的RNA结合结构域与其靶RNA的复合物结构，阐明了其特异性识别序列及调控RNA剪接的分子基础。
3. **文献名称**：*Generation and functional characterization of recombinant TRA2A protein for splicing assays*
**作者**：Kuroyanagi et al., 2015
**摘要**：开发了重组TRA2A蛋白的高效原核表达系统，验证了其在体外剪接实验中增强特定外显子保留的功能，为后续机制研究提供了工具。
*注：以上为模拟示例，实际文献需通过PubMed/Google Scholar检索确认。*
Recombinant human TRA2A (Transformer-2 Alpha) protein is a key regulator of RNA splicing, belonging to the SR (serine/arginine-rich) protein family. TRA2A plays a critical role in pre-mRNA splicing by binding to specific RNA sequences, particularly purine-rich exonic elements, to facilitate spliceosome assembly and regulate alternative splicing events. Structurally, it contains an RNA recognition motif (RRM) domain essential for RNA binding and RS domains involved in protein-protein interactions.
TRA2A is ubiquitously expressed and vital for cellular processes, including cell cycle regulation, differentiation, and apoptosis. Dysregulation of TRA2A has been linked to various cancers, where its overexpression often correlates with tumor progression, metastasis, and poor prognosis. It also contributes to neurological disorders, such as ALS and spinal muscular atrophy, by affecting splicing of neuronal transcripts.
Recombinant TRA2A is typically produced in *E. coli* or mammalian expression systems, enabling functional studies on its splicing activity, RNA-binding properties, and interaction with spliceosomal components. This protein serves as a valuable tool for investigating splicing mechanisms, developing RNA-targeted therapies, and exploring diagnostic biomarkers for diseases linked to splicing defects. Current research focuses on its therapeutic potential in modulating aberrant splicing pathways in cancer and neurodegenerative diseases.
×
